Association of Ustekinumab Trough Concentrations With Clinical, Biochemical and Endoscopic Outcomes

被引：7
|
作者：
Battat, Robert
Kopylov, Uri
Bessissow, Talat
Bitton, Alain
Cohen, Albert
Martel, Myriam
Seidman, Ernest G.
Afif, Waqqas
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)30587-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
696
引用
收藏
页码：S144 / S145
页数：2
相关论文
共 50 条
  • [21] Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease
    Papamichael, Konstantinos
    Rakowsky, Shana
    Rivera, Claudio
    Cheifetz, Adam S.
    Osterman, Mark T.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2266 - 2271
  • [22] Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn's disease
    Yanofsky, R.
    Abduallah, Y.
    Golovics, P.
    Lakatos, P. L.
    Bitton, A.
    Wild, G.
    Afif, W.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I522 - I522
  • [23] Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn's disease
    Yanofsky, R.
    Abduallah, Y.
    Golovics, P.
    Lakatos, P. L.
    Bitton, A.
    Wild, G.
    Afif, W.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I522 - I522
  • [24] ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN'S DISEASE
    Di Fonzo, David M.
    Alabdulkarim, Balqis
    Yanofsky, Russell
    Abduallah, Yaqeen
    Golovics, Petra A.
    Lakatos, Peter L.
    Bitton, Alain
    Wild, Gary
    Afif, Waqqas
    Bessissow, Talat
    GASTROENTEROLOGY, 2023, 164 (06) : S882 - S883
  • [25] Higher Ustekinumab Concentrations in Induction are associated With Better Endoscopic Outcomes in Inflammatory Bowel Disease
    Serra-Ruiz, X.
    Cespedes-Martinez, E.
    Ayala, L. Mayorga
    de Guise, C. Herrera
    Robles, V
    Lastiri, E.
    Garcia-Garcia, S.
    Larrosa-Garcia, M.
    Martinez, M. T. Sanz
    Martinez, Z. Perez
    Oller, E.
    Borruel, N.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1551 - i1552
  • [26] Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease
    Dominguez, Francisco Angel Lao
    Lozano, Maria Jose Fobelo
    Pizarraya, Antonio Gutierrez
    Fernandez, Manuel Castro
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (08): : 631 - 632
  • [27] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [28] Correlation of Ustekinumab Trough Levels With Outcomes in Inflammatory Bowel Disease
    Petrov, Jessica C.
    Fine, Sean
    Alzahrani, Raneem
    Mohamed, Gamal
    Al-Bawardy, Badr
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S703 - S704
  • [29] Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn's Disease
    Kwon, Yiyoung
    Kang, Ben
    Kim, Eun Sil
    Choe, Yon Ho
    Kim, Mi Jin
    THERAPEUTIC DRUG MONITORING, 2022, 44 (04) : 535 - 542
  • [30] Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel disease
    Serra-Ruiz, X.
    Martinez, E. Cespedes
    Ayala, L. Mayorga
    De-Guise, C. Herrera
    Alonso, V. Robles
    Martinez, Z. Perez
    Oller, E.
    Sainz, N. Borruel
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1619 - I1620
12345